NU6102,
O(6)-cyclohexylmethoxy-2-(4'-sulfamoylanilino)purine,
nu6102,
444722-95-6,
NU 6102,
NU-6102,
O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE,
Cdk1/2 Inhibitor II, NU6102,
6-Cyclohexylmethoxy-2-(4′-sulfamoylanilino)purine,
4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}benzenesulfonamide,
4SP,
1h1s,
4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide,
4-[[6-(cyclohexylmethoxy)-9h-purin-2-yl]amino]benzenesulfonamide,
4-{[6-(cyclohexylmethoxy)-7h-purin-2-yl]amino}benzenesulfonamide,
4eok,
4eor,
2c6o,
2iw8,
2iw9,
AC1L1IGA,
BDBM5544,
CHEMBL319467,
SCHEMBL2170816,
SCHEMBL12589612,
CTK1D2419,
CTK7F2153,
CTK8G2090,
DTXSID70274438,
ZINC3873287,
HSCI1_000264,
IN1395,
DB07126,
NCGC00346950-01,
NCGC00346950-03,
A12438,
K00275,
6-Cyclohexylmethoxy-2-(4 -sulfamoylanilino)purine,
4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}benzene-1-sulfonamide,
Benzenesulfonamide, 4-[[6-(cyclohexylmethoxy)-1H-purin-2-yl]amino]-,
D0Y5RO,
CID4566,
OWXORKPNCHJYOF-UHFFFAOYSA-N,
C466914,
O(6)-cyclohexylmethoxy-2-(4'-sulfamoylanilino)purine,